Free Trial

Ambrx Biopharma (AMAM) Earnings Date, Estimates & Call Transcripts

Notice: This company has been marked as potentially delisted and may not be actively trading.
Skip Charts & View Estimated and Actual Earnings Data

AMAM Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

AMAM Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ambrx Biopharma Analyst EPS Estimates

Current Year EPS Consensus Estimate:($1.45) EPS
Next Year EPS Consensus Estimate: ($1.28) EPS

Ambrx Biopharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/9/2023Q2 2023($0.28)($0.05)+$0.23($0.05)$1.50 million$1.12 million
5/11/2023Q1 2023-($0.05)($0.05)($0.05)-$0.02 million
4/26/2022Q4 2021-($0.48)($0.48)($0.48)-$7.46 million

Ambrx Biopharma Earnings - Frequently Asked Questions

How much revenue does Ambrx Biopharma generate each year?

Ambrx Biopharma (NYSE:AMAM) has a recorded annual revenue of $7.40 million.

How much profit does Ambrx Biopharma generate each year?

Ambrx Biopharma (NYSE:AMAM) has a recorded net income of -$78 million. AMAM has generated $0.00 earnings per share over the last four quarters.

What is Ambrx Biopharma's EPS forecast for next year?

Ambrx Biopharma's earnings are expected to grow from ($1.45) per share to ($1.28) per share in the next year.


More Earnings Resources from MarketBeat

This page (NYSE:AMAM) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners